What does merger-related charges and other mean?

Captures non-cash expenses incurred during the integration or acquisition of other entities, such as asset write-downs or impairment charges. This metric helps investors isolate the impact of inorganic growth activities from core operational performance. It provides transparency into the true cost of business combinations.

Dogwood Therapeutics DWTX Merger-related charges and other

Merger-related charges and other at other companies

CTO

Citius Oncology, Inc.CTOR

$2.75M0.0%

SB Financial GroupSBFG

$700K0.0%

ROC

Rank One Computing ROC

$32.83K-11.6%

Dogwood TherapeuticsDWTX

$890.82K—

KEE

Keel Infrastructure Corp. Common StockKEEL

$1.77M—

Alto Ingredients, Inc.ALTO

-$115K-106%

Other financials

Income statement

See full

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Balance sheet

See full

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Cash flow

See full

Operating cash flow-$4.6M+2.0%

Valuation

See full

Market cap$54.14M-54.2%

Enterprise value$41.06M-60.9%

Returns & leverage

See full

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NoncashMergerRelatedCosts.

The official record: Dogwood Therapeutics’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's merger-related charges and other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dogwood Therapeutics's merger-related charges and other?: Dogwood Therapeutics (DWTX) reported merger-related charges and other of $890.82K in Q4 2024.
What does merger-related charges and other mean?: Captures non-cash expenses incurred during the integration or acquisition of other entities, such as asset write-downs or impairment charges. This metric helps investors isolate the impact of inorganic growth activities from core operational performance. It provides transparency into the true cost of business combinations.